Simtra Opens $250 Million Sterile Injectables Expansion in Bloomington: 18 Filling Lines by 2027

News, 13 November 2026. Every news figure below comes from a linked source, and the full list is at the end.

What Simtra announced on 9 November 2026

In a press release, the contract manufacturer described the opening of its Bloomington expansion.

• Bloomington, Building H: an investment of more than $250 million in a building of 153,000 square feet.
• Germany: more than $125 million in expanded manufacturing capacity in Halle, Westfalen.
• Lines: the company says its network grows from 11 to 18 filling lines across the US and Europe by 2027.
• Earlier step: an initial investment of more than $150 million at the Bloomington Park campus.
• Jobs: the release speaks of hundreds of jobs without an exact number.

The release says the new building adds prefilled syringe, vial and lyophilization capability. The release gives no line speeds or start dates per line, so we make no claim about them.

The numbers behind the news

Simtra's opening release and its October 2025 update give a fairly complete picture of the network plan. The table combines both.

Sources: Simtra, release of 9 November 2026, Simtra, release of 27 October 2025, and the Indiana Economic Development Corporation, release of 11 June 2024. The opening release went out on 9 November 2026 at 15:32 US Eastern time.

Two things stand out. First, the investment is spread over three projects on two continents, so the 11 to 18 lines will not all start at one site or at one time. Second, the October 2025 release ties the first new vial line to highly potent molecules and three lyophilizers, and on lines of that type freeze-drying cycle time can become the pacing step. What the figures do not say: no line speeds, no batch sizes, no start date per line, no split of the 200 million units by site or format, and no exact job count. The only job number on record is the state's: the IEDC based its tax credits on plans for up to 130 jobs, and the company can claim those credits only once people are hired and trained. The 2024 plan said 150,000 square feet; the opened building is 153,000. Any capacity per line you read elsewhere is an estimate, not a company figure.

Why sterile injectable capacity matters beyond one company: the US Department of Health and Human Services' planning office, ASPE, found in January 2025 that injectable products made up about half (1,018) of the US drug shortages it counted from 2018 to 2023, and that injectable shortages lasted a median of 4.6 years, against 1.6 years for oral products. Lost hours on a sterile filling line are therefore not only a cost line; for some products they decide whether supply keeps up.

Why it matters now

This opening is one step in a build-out Simtra has described in stages. In its October 2025 release, the company said it had added a flexible clinical line in Bloomington for prefilled syringes and for liquid and freeze-dried vials, and was building a facility for three isolator commercial-scale filling lines. In Halle it had opened a building with two high-speed isolator lines, one for syringes and one for vials, and a conjugation and purification suite. It said it makes six of the 17 approved antibody-drug conjugates.

The building itself goes back further. On 11 June 2024 the Indiana Economic Development Corporation described a $250 million, 150,000 square foot Simtra facility in Bloomington with two high-speed isolator syringe lines and a high-speed isolator vial line with three lyophilizers. The state committed up to $1.6 million in conditional tax credits, based on plans for up to 130 jobs. Those figures match Building H closely, although the IEDC page does not use that name.

The Building H opening turns part of that plan into floor space. The release frames it around customer demand, with the chief operating officer saying customers plan years ahead. For people who run sterile lines, the lesson is the timing. Isolator lines move from mechanical completion through commissioning, qualification, media fills and process validation before a commercial batch is released. Each of those stages has its own losses, and the habits a team forms in the first months of a line tend to stay. A network adding seven lines by 2027 has seven chances to set those habits well, or to carry the same early losses into every new line.

In context: what the regulators require before a new line ships

Every new aseptic line has to prove itself with media fills, also called aseptic process simulation, before commercial batches. The US FDA's guidance on sterile drug products produced by aseptic processing, dated September 2004 and announced in October 2004, recommends at least three consecutive successful runs at initial line qualification, then semi-annual requalification for each line, and calls 5,000 to 10,000 units a generally acceptable starting run size. In the EU, the revised GMP Annex 1 for sterile medicinal products, published on 25 August 2022 and in operation since 25 August 2023, asks for at least three consecutive satisfactory simulations that cover all working shifts, repeated about every six months for each line and each shift. It also sets glove integrity testing on isolators at least at the beginning and end of each batch or campaign.

The arithmetic for a growing network follows. Seven new lines need at least 7 x 3 = 21 initial simulation runs before release. After that, 18 lines on a single shift pattern need at least 18 x 2 = 36 periodic runs a year, and more for every extra shift. Each run takes line time that produces nothing saleable, so it belongs in the capacity plan and in OEE as planned time, not as an unexplained gap.

What it means for a sterile filling site

Going from 11 to 18 lines is an increase of about 64%. For any sterile filling network, new lines are only half of the story. The other half is how fast each line reaches stable, released output.

Aseptic lines lose time in their own ways. Each batch or product change can bring line clearance, cleaning and sterilisation of product-contact parts, environmental monitoring and set-up checks. Media fills and qualification runs take time before commercial batches. Short stops inside the isolator or RABS, a jammed stopper bowl or a weight check that drifts, are frequent but small, and easy to lose in a shift report.

We have no view of how Simtra runs its lines and make no guess about it. The questions apply to any site starting new filling lines.

Where a filling week goes: a worked example

Example data, not Simtra's. One vial filling line, 120 planned hours a week, three product changes.

The four rows add up to 24 + 12 + 6 + 78 = 120 hours. Cutting each changeover from 8 to 6 hours gives back 3 x 2 = 6 hours a week, as much as halving the short-stop loss would at this split. That is why campaign planning and changeover standard work often pay first on aseptic lines.

Starting up new sterile filling lines? Book a demo and see changeovers, short stops and rejects per line and shift.

What it means for plant, production and maintenance managers

Plant manager: commit capacity in stages, by measured line performance

On a contract filling site, the plant manager signs up capacity that clients plan years ahead. If a new isolator line is promised to clients at its design rate from day one, any shortfall in ramp-up lands on the client's launch date. A safer pattern is to commit in stages: a share of design capacity for the first two quarters after release, raised only when the line has shown it for several consecutive weeks. Tie the stages to measured OEE, not to the validation calendar. Watch the people side too. Every new aseptic line needs gowned, qualified operators, and qualification of a new operator takes time. If the same experienced crew is pulled from running lines to start new ones, existing lines can lose performance while new lines ramp. Track OEE on the old lines through the start-up period as a check on that.

Production manager: plan campaigns around the slowest step

On a vial line with freeze-drying, the filler is often not the pacing step. If a lyophilization cycle takes days and the line has three freeze-dryers, the line can only fill as fast as dryers come free, and the fill schedule must follow the dryer calendar. Record that wait as its own stop reason, so it is not mistaken for a filler problem. Highly potent products add containment steps at changeover, and the change from one potent product to another can take longer than a standard product change. Plan campaigns so that like products run together and the longest cleaning steps happen as rarely as possible. Keep a changeover log by product pair, with start and end times for clearance, cleaning, decontamination and set-up, so the team learns which pairs cost most and can sequence around them.

Maintenance manager: the first year decides the reliability baseline

New isolator lines bring a long list of new failure points: glove ports, transfer ports, stopper and cap feeding, weighing stations, decontamination generators and freeze-dryer vacuum and refrigeration systems. Many early failures in a new line come from settings, sensor alignment and part fit rather than worn parts. Log each stop with the machine section and a reason from the first commercial batch, and review the top ten each week with the equipment supplier while the warranty period runs. Build the spares list from those stops, not only from the supplier's recommended list. Schedule preventive work into planned changeovers and decontamination cycles where the cleaning validation allows it, so the isolator is not opened twice. Keep glove integrity test results next to stop data; a rising glove failure rate is an early signal before it becomes a batch deviation.

Three steps to measure a new filling line from its first batch

1. Record changeover and sterilisation as their own stops. With a start, an end and the product pair, so campaign plans can be compared. Our guide to OEE for aseptic filling lines covers run length and re-sterilisation.
2. Keep short stops visible. Take run and stop signals from the filler PLC, so minor stops are counted, not averaged away.
3. Agree the ramp target in writing. Expected OEE for the first batches and for steady state, reviewed weekly by operations and quality. For the wider picture, see OEE in pharmaceutical manufacturing.

What to do this quarter

• Define the ramp curve per new line. Write expected OEE at first release, at 3 months and at 6 months, signed by operations and quality. In the example below, 10 points of performance on one vial line were worth USD 57,600 a week (Example data).
• Log dryer waits separately. Add a stop reason for a filled batch waiting for a free lyophilizer, and report its hours each week.
• Build a product-pair changeover matrix. Record every changeover with both products and each step's duration; rank the five most costly pairs within 8 weeks.
• Put media fills in the capacity plan. Book at least three initial runs per new line and two periodic runs per line and shift each year, and show them as planned time in OEE.
• Protect the running lines. Track OEE on existing lines during each new line's start-up; investigate any drop of more than 3 points.
• Review the top ten stops with the supplier weekly. During the warranty period, the maintenance manager brings section-level stop data to each review.
• Size the qualified crew before release. Count gowning-qualified operators per shift for every line; do not release a line that needs crew borrowed from another.
• Tie PM to decontamination cycles. List PM tasks that need the isolator open and schedule them inside planned changeovers.

Where OEE and light MES help

OEE per line splits a filling week into availability, performance and quality, so changeovers, short stops and rejects each get their own owner. A light MES adds batches, products and the reasons operators enter, so a changeover on Tuesday can be compared with the same changeover last month.

Which OEE factor a new filling line touches most

During ramp-up, performance usually lags. A new line often runs below its design speed while settings, feeding and weighing are tuned, and any speed change on a validated line goes through change control. The performance factor shows how much output that slower running costs.

Example data, not Simtra's. A vial line has a design speed of 300 vials a minute and 80 hours of run time a week. At design speed it could fill 80 x 60 x 300 = 1,440,000 vials. It fills 1,152,000, so performance is 1,152,000 / 1,440,000 = 80%. Assume the average speed is raised to 270 vials a minute after validation (Example data). Output becomes 80 x 60 x 270 = 1,296,000 vials, performance 90%, and the line gains 144,000 vials a week with no extra run time.

What 10 points of performance are worth (Example data). Assume a contribution of USD 0.40 per vial, 45 production weeks a year, and that the extra vials are released at the same rate as the rest (all Example data). The gain is 144,000 x USD 0.40 = USD 57,600 a week, and USD 57,600 x 45 = USD 2,592,000 a year, from one line with no extra run time. On a contract site that money is only real if a client has ordered the extra volume, which is why the plant manager commits capacity in stages.

How Fabrico does it

Fabrico is a cloud OEE and light MES platform. It shows OEE and losses by line and shift from the PLC or a Fabrico IoT device, with the reasons operators add on a tablet or phone. On manual packing stations after filling, AI cameras (an add-on) count output. We have no link to Simtra; the news figures above are from its releases and the public sources linked.

Planning campaigns across several filling lines? Book a demo.

What people ask next

What did Simtra open in Bloomington?

On 9 November 2026 Simtra BioPharma Solutions opened Building H in Bloomington, Indiana, an expansion of more than $250 million and 153,000 square feet for sterile injectables, according to its press release.

How many filling lines will Simtra have?

Simtra says its network grows from 11 to 18 filling lines across the US and Europe by 2027, helped by more than $125 million of expanded capacity in Halle, Germany.

Where should an aseptic filling line look for lost time first?

It varies by site, but changeovers with cleaning and sterilisation, short stops inside the isolator or RABS, and rejected units are the usual places to look first. See our guide to OEE for aseptic filling lines.

What else has Simtra added besides Building H?

In its release of 27 October 2025, Simtra said it added a flexible clinical line in Bloomington, bought a 65-acre property with more than 300,000 square feet of space, and opened a Halle building with two high-speed isolator lines. It plans at least six more isolator filling lines on the new campus.

Why does freeze-drying limit a vial filling line?

A lyophilization cycle can take far longer than filling the batch, so a filled batch may wait for a free freeze-dryer. Simtra's first new isolator vial line has three lyophilizers, per its October 2025 release. Logging dryer waits as their own stop reason shows how much line time they cost.

Sources

All sources accessed on 14 November 2026. Dates are the publication dates shown on each page.

• Simtra BioPharma Solutions, Simtra BioPharma Solutions celebrates opening of $250 million Bloomington manufacturing expansion (PR Newswire), 9 November 2026
• Simtra BioPharma Solutions, Simtra BioPharma Solutions expands global manufacturing footprint to advance the future of sterile injectables (PR Newswire), 27 October 2025
• Indiana Economic Development Corporation, Gov. Holcomb celebrates another life sciences win in Bloomington with Simtra BioPharma Solutions, 11 June 2024
• US Food and Drug Administration, Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing, Current Good Manufacturing Practice, September 2004
• European Commission, EudraLex Volume 4, EU GMP Annex 1: Manufacture of Sterile Medicinal Products, 25 August 2022
• US Department of Health and Human Services, ASPE, Analysis of Drug Shortages, 2018-2023, 14 January 2025